A5024537133- Ophthalmology and Eye Disorders
- SARS-CoV-2 and COVID-19 Research
- Microscopic Colitis
- Nosocomial Infections in ICU
- Thyroid Disorders and Treatments
- Neuropeptides and Animal Physiology
- Clostridium difficile and Clostridium perfringens research
- Long-Term Effects of COVID-19
- Growth Hormone and Insulin-like Growth Factors
- Peripheral Neuropathies and Disorders
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Viral Infections and Outbreaks Research
University Hospital Frankfurt
2024
Goethe University Frankfurt
2024
University Medical Center of the Johannes Gutenberg University Mainz
2023
Johannes Gutenberg University Mainz
2023
Background: Treatment of Graves' hyperthyroidism (GH) and orbitopathy (GO) is far from adequate, hence, new substances that specifically target the autoantigens in GH/GO are warranted. This study determined preclinical vitro efficacy SYD5115, a novel low-molecular-weight compound inhibits thyrotropin receptor (TSH-R). Methods: The TSH-R inhibiting capability SYD5115 was tested through stimulation wild-type chimeric expressed Chinese hamster ovary (CHO) cells using two functional (stimulatory...
Yellow fever (YF) is a potentially lethal viral hemorrhagic that can be prevented with the 17D live attenuated YF vaccine. However, this vaccination cause severe adverse reactions including vaccine-associated YF. Here, we describe case of 32-year-old female who was permanently immunosuppressed an anti-CD20 antibody due to multiple sclerosis. Following vaccination, patient developed, variety symptoms such as febrile temperatures, muscle and joint pain, headaches, dysuria. A yellow viremia...
Abstract mRNA-based vaccines played a key role in fighting the global COVID-19 pandemic by saving millions of lives. In rare cases, however, BNT162b2 vaccine has been associated with severe adverse reactions e.g. myocarditis (OE ratio 2.78; 95% CI 2.61; 2.95) [Faksova Vaccine 42(9):2200-2211, 2024, https://doi.org/10.1016/j.vaccine.2024.01.100 , Schwab Clin Res Cardiol 112(3):431-440, 2022, https://doi.org/10.1007/s00392-022-02129-5 ]. Here, we describe case 38-year-old man who developed...
Abstract Disclosure: G.J. Kahaly: None. A. George: L. Steiner: T. Weirauch: J. Henseling: Frommer: Wolf: Background & aims: Treatment of both Graves’ hyperthyroidism (GH) and orbitopathy (GO) is still far from adequate, hence new therapeutic modalities, which specifically target the autoantigens in GH/GO, are warranted. This study determined preclinical vitro efficacy SYD5115, a novel thyrotropin receptor (TSH-R) antagonist. Methods: SYD5115 nanomolar potent low molecular weight TSH-R...